Larvol Delta - Cognition-Therapeutics-ProofofConcept-Phase-2-SHINE-Trial-Demonstrates-Consistent-Improvement-in-Cognitive-Outcomes-with-OnceDaily-Oral-CT1812-in-MildtoModerate-Alzheimers-Patients

Elayta (CT1812) - Cognition Therap

https://www.globenewswire.com/news-release/2024/07/29/2920165/0/en/Cognition-Therapeutics-Proof-of-Concept-Phase-2-SHINE-Trial-Demonstrates-Consistent-Improvement-in-Cognitive-Outcomes-with-Once-Daily-Oral-CT1812-in-Mild-to-Moderate-Alzheimer-s-Pa.html

Jul 29, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next